Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Jul 11.
Published in final edited form as: Cancer Prev Res (Phila). 2022 Jun 2;15(6):412. doi: 10.1158/1940-6207.CAPR-22-0203

Retraction: Carnosol, a Constituent of Zyflamend, Inhibits Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and Mutagenesis

Arash Mohebati, Joseph B Guttenplan, Amit Kochhar, Zhong-Lin Zhao, Wieslawa Kosinska, Kotha Subbaramaiah, Andrew J Dannenberg
PMCID: PMC9272761  NIHMSID: NIHMS1821958  PMID: 35652229

This article (1) has been retracted at the request of the authors. There was evidence of data falsification or fabrication found in two panels of Fig. 4. Suspicious duplications of band images were found in Fig. 4A and Fig. 4B, and evidence is consistent with these bands being three sets of duplicates. A copy of this Retraction Notice was sent to the last known e-mail addresses for the 7 authors. Three authors (Z.-L. Zhao, K. Subbaramaiah, and A.J. Dannenberg) agreed to the retraction; 4 authors (A. Mohebati, J.B. Guttenplan, A. Kochhar, and W. Kosinska) did not respond. The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

Reference

  • 1.Mohebati A, Guttenplan JB, Kochhar A, Zhao ZL, Kosinska W, Subbaramaiah K, et al. Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis. Cancer Prev Res 2012;5:593–602. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

RESOURCES